Pfizer to shutter Indian site
This article was originally published in Scrip
Pfizer's last remaining Indian manufacturing facility in Thane will be closed down from 16 September, the second recent plant-related action by a foreign firm after Sandoz said that it intended to discontinue operations at its Turbhe unit by the end of next year. Both facilities are located in the western state of Maharashtra.
You may also be interested in...
Pfizer is ending operations at two Indian manufacturing sites, including one with a checkered regulatory history. Approximately 1,700 jobs are at stake as a result of the action, though the US multinational clarified that it is not making a widespread exit from Indian manufacturing.
Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.
Indian investigating agency probes alleged bribe paid to drugs regulator in a case pertaining to the approval process of Biocon Biologics’ insulin aspart. The company strongly denies the allegations, underscoring that all its product approvals are backed by science and clinical data.